A Real-World Study of the Influencing Factors of Antipsychotic Medication Use Dosage in Patients with Schizophrenia
DONG Wen-tian, CHI Rui, YU Xin, HE Yong, SI Tian-mei*
Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing 100191, China
Abstract：OBJECTIVE To analyze the prescription dosage of antipsychotics, and explore the influencing factors of high-dose medication through descriptive research on the dosage of antipsychotics. METHODS A retrospective longitudinal study was carried out using electronic medical records of Peking University Sixth Hospital. The characteristics of patients′ antipsychotic medications were described through real-world studies, and the cumulative average daily dose of antipsychotics in adult patients with schizophrenia was analyzed.Logistic regression was used to analyze the influencing factors of high-dose medication. RESULTS ①The 95.3% of the patients used second-generation antipsychotics, 97.2% used oral dosage forms, 71.9% used two or more antipsychotics at the same time during the follow-up period, and 17.9% of the patients were hospitalized during the follow-up period; ②The cumulative average daily dose of 56.3% patients was medium dose, and the proportion of low dose was higher than that of high dose. The cumulative average daily dose distribution of patients in each layer is similar to the overall patient; ③The combined use of multiple antipsychotics increased the cumulative average daily dose, and the corrected OR is 3.0 (high dose vs non-high dose) and 8.2 (high dose vs low dose), 2.3 (high dose vs medium dose). During the follow-up period, whether the hospitalization affects the cumulative average daily dose to reach the high dose, the multi-factor regression RESULTS are inconsistent; ④The RESULTS indicated that the combined use of multiple antipsychotics increases the cumulative average daily dose, and the consequences of the combined use of multiple antipsychotics should be vigilant. CONCLUSION The RESULTS of the study can be used to explore the possibility of evaluating the rationality of patients′ medication and warning of adverse drug reactions based on the cumulative average daily dose.
董问天, 迟锐, 于欣, 贺勇, 司天梅. 精神分裂症患者抗精神病药使用剂量真实世界研究[J]. 中国药学杂志, 2022, 57(8): 663-668.
DONG Wen-tian, CHI Rui, YU Xin, HE Yong, SI Tian-mei. A Real-World Study of the Influencing Factors of Antipsychotic Medication Use Dosage in Patients with Schizophrenia. Chinese Pharmaceutical Journal, 2022, 57(8): 663-668.
TORNIAINEN M, MITTENDORFER-RUTZ E, TANSKANEN A, et al. Antipsychotic treatment and mortality in schizophrenia [J]. Schizophr Bull, 2015, 41(3): 656-663.
[2]
RAY W A, CHUNG C P, MURRAY K T, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death [J]. N Engl J Med, 2009, 360(3): 225-235.
[3]
RAY W A, STEIN C M, MURRAY K T, et al. Association of antipsychotic treatment with risk of unexpected death among children and youths [J]. JAMA Psychiatry, 2019, 76(2): 162.
[4]
ROH D, CHANG J G, KIM C H, et al. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: A 5-year comparison [J]. Aust N Z J Psychiatry, 2014, 48(1): 52-60.
[5]
ROH D, CHANG J G, YOON S, et al. Antipsychotic prescribing patterns in first-episode schizophrenia: A five-year comparison [J]. Clin Psychopharmacol Neurosci, 2015, 13(3): 275-282.
[6]
QIU H, HE Y, ZHANG Y, et al. Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan [J]. Aust N Z J Psychiatry, 2018, 52(12): 1202-1212.
[7]
CHEN J L, ZHANG M, LI L X, et al. Review of antipsychotic drugs utilization in two major psychiatric hospital in Guangzhou during 2010-2014 [J]. Pharm Today(今日药学), 2015, 25(5): 343-346.
[8]
ZHANG X, XU L C, HUANG K. Analysis of the utilization of antipsychotic drugs in 26 hospitals from Hangzhou area during 2009-2011 [J]. J China Pharm(中国药房), 2013, 24(22): 2035-2038.
[9]
ZHANG Y S, WANG J, XU N, et al. The frequency of the use of antipsychotics in a provincial mental health center from 2002 to 2011 [J]. Chin Gen Pract(中国全科医学), 2016, 19(11): 1342-1346.
[10]
WHO. ATC/DDD Index 2020 [S]. 2021, Oslo, Norway: World Health Organization.
[11]
WHO. International working group for drug statistics methodology, drug utilization metrics and their applications. introduction to drug utilization research [S]. 2003, Oslo, Norway: World Health Organization, 38-41.
[12]
CARMONA-HUERTA J, CASTIELLO-DE O S, RAMIREZ-PALOMINO J, et al. Polypharmacy in a hospitalized psychiatric population: risk estimation and damage quantification [J]. BMC Psychiatry, 2019, 19(1): 78.
[13]
BERLING I, BUCKLEY N A, ISBISTER G K. The antipsychotic story: changes in prescriptions and overdose without better safety [J]. Br J Clin Pharmacol, 2016, 82(1): 249-254.
[14]
CAO G Y, WANG C G, CHEN M H, et al. Rhabdomyolysis after antipsychotic use: case reports and literature review[J]. Chin Pharm J(中国药学杂志), 2019, 54(18): 1527-1533.
2022, Vol. 57 
